Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer [Thoracic Oncology]
Conclusion
The safety profile of nivolumab plus PT-DC was consistent with that expected for individual agents; however, treatment discontinuation related to AEs was greater with the combination. Encouraging activity was observed, especially for the nivolumab 5 mg/kg plus paclitaxel-carboplatin group, with a 2-year OS rate of 62%.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Rizvi, Hellmann, Brahmer, Juergens, Borghaei, Gettinger, Chow, Gerber, Laurie, Goldman, Shepherd, Chen, Shen, Nathan, Harbison, Antonia Tags: Chemotherapy Thoracic Oncology Source Type: research
More News: Alimta | Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Study | Toxicology